Abstract: INFO11-SA
The Clinical Phenotyping Resource and Biobank Core (C-PROBE)
Session Information
- Informational Posters - 3
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- No subcategory defined
Authors
- Bitzer, Markus, University of Michigan, Ann Arbor, Michigan, United States
- Gadegbeku, Crystal A., Cleveland Clinic, Cleveland, Ohio, United States
- Lienczewski, Chrysta C., University of Michigan, Ann Arbor, Michigan, United States
- Ju, Wenjun, University of Michigan, Ann Arbor, Michigan, United States
- Pennathur, Subramaniam, University of Michigan, Ann Arbor, Michigan, United States
- Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
Description
The Clinical Phenotyping Resource and Biobank Core (C-PROBE) has enrolled over 1700 patients with CKD from 5 sites and banked their samples and clinical information providing a valuable resource for efficient discovery over the past 15 years, including over 275 children and 1400 adults with varying stages of chronic kidney disease. The primary CPROBE goal is to develop an infrastructure that serves as an interface between patients in the clinical care settings and biomedical investigators conducting translational research in kidney disease. Multiple specific research studies have now successfully utilized these resources. Participants are enrolled at a baseline visit, and followed annually at regularly scheduled clinical care appointments, in which data updates are procured as well as biospecimens, including blood and urine. Current disease etiology breakdown is 37% Glomerular, 16% Diabetic Nephropathy, 18% Tubulointerstitial, 16% Hypertension, 1% CAKUT, 12% Hereditary/Other. Biological specimens include remnant kidney tissue, blood including plasma (EDTA), serum (SST), DNA and RNA, and urine preserved with both protease inhibitor and sodium azide. Demographic data collected annually includes age (at enrollment), annual household income, educational level, race and ethnicity, gender, height and weight, employment status, and primary type of work, among others. Gender breakdown is 52% female, 48% male; with race representation of 1% American Indian/Alaskan Native, 3% Asian/Asian American, 39% Black/African American, 52% Caucasian/White, 3% Multiracial and 1% Not reported. 9% Self identify as Hispanic. 33.78% of Black participants experienced 40% or greater decline in eGFR, with 41.18% of white participants having the same decline. All-cause mortality of 11.95% Black and 9.32% white were also observed. The study has 45,600 plasma and serum samples, 53,400 urine derived samples, and remnant tissue in RNA-Later from 129 renal biopsies.
Funding
- The Renal Pre-Competitive Consortium (RPC^2)